Integra LifeSciences
IART
235 hedge funds and large institutions have $3.9B invested in Integra LifeSciences in 2018 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 66 increasing their positions, 87 reducing their positions, and 28 closing their positions.
86% more call options, than puts
Call options by funds: $371K | Put options by funds: $199K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 28
14% more capital invested
Capital invested by funds: $3.42B → $3.9B (+$486M)
6% more funds holding
Funds holding: 221 → 235 (+14)
0.91% less ownership
Funds ownership: 90.96% → 90.04% (-0.91%)
24% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 87
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
+$30.5M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$18.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$13M |
| 4 |
BlackRock
New York
|
+$12.4M |
| 5 |
CBT
Capital Bank & Trust
Irvine,
California
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$34.1M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$24.2M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$16.6M |
| 4 |
State Street
Boston,
Massachusetts
|
-$14.5M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$11.9M |
IART Hedge Fund Activity: Q1 2018 in Review
235 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2018, worth a combined $3.9B — up 14% from $3.42B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new IART positions and 28 closed out — a net gain of 14 holders — while 66 added to existing stakes and 87 trimmed.
The largest buyer was Westwood Holdings Group, opening a new position worth an estimated $30.5M. The largest seller was OrbiMed, exiting entirely with an estimated $34.1M sold.
- 235 institutional investors held Integra LifeSciences (IART) as of Q1 2018, up from 221 in Q4 2017.
- Funds reported $3.9B of Integra LifeSciences stock for Q1 2018, up 14% quarter-over-quarter.
- 42 funds opened new Integra LifeSciences positions in Q1 2018 and 28 closed out, a net change of +14 holders.
- The largest Integra LifeSciences buyer in Q1 2018 was Westwood Holdings Group, an estimated $30.5M added.
- The largest Integra LifeSciences seller in Q1 2018 was OrbiMed, an estimated $34.1M sold.
Based on aggregated 13F filings for Q1 2018.